STAT Plus: New bill would create a subscription payment model to jumpstart antibiotic development
In a bid to combat antimicrobial resistance, two U.S. lawmakers have introduced a bipartisan bill…
Category: STAT Plus
STAT Plus: With a new CEO, a small biotech is out to prove Wall Street wrong
G1 Therapeutics, a North Carolina biotech company, is changing CEOs on the eve of an…
STAT Plus: For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit
A federal judge ruled that a Texas county can proceed with a lawsuit accusing several…
STAT Plus: Pharmalittle: Trump still insists a Covid-19 vaccine is ‘weeks away’; Regeneron antibody treatment shows promise
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT Plus: Telehealth startup Ro expands partnership with Pfizer to provide generic drugs
Telehealth startup Ro is expanding its partnership with pharma giant Pfizer’s generics arm to offer…
STAT Plus: The health tech tracker for the fourth quarter: 14 pivotal industry events to watch
Welcome to STAT’s Health Tech Tracker, a ledger of all the major data readouts, product…
STAT Plus: For two decades, the FDA approval process for opioids had numerous shortcomings, study finds
Over more than two decades, the Food and Drug Administration approved opioid painkillers based on…
STAT Plus: Catalyst loses lawsuit accusing the FDA of unfairly approving a rival rare disease drug
In a blow to Catalyst Pharmaceuticals (CPRX), a federal judge dismissed its lawsuit accusing the…
STAT Plus: Pharmalittle: Biden getting more pharma donations than Trump; FDA safety plan not ‘well suited’ for opioids
Good morning, everyone, and nice to be back after an extended weekend break. Nonetheless, time…
STAT Plus: Drug industry CEOs will testify this week about some of pharma’s most controversial medicines
The House Oversight Committee will hold two days of hearings this week with six drug…
STAT Plus: An FDA safety program is failing to stem the opioid crisis — and manufacturers are mostly to blame
A mandated safety program regulators rely on to minimize opioid abuse and misuse is not…
STAT Plus: With a new law, California becomes the first state to pursue its own line of generics
In a groundbreaking move, California adopted a law Monday to allow the state to develop…
STAT Plus: Pharmalittle: Operation Warp Speed is more Army than science; J&J’s Covid-19 vaccine moves forward
Good morning, one and all. Damian Garde here, filling in for Ed Silverman at the…
STAT Plus: The 8 most important leaders of Operation Warp Speed
Below are the eight most important people leading Operation Warp Speed. It is based on…
STAT Plus: ‘The largest application we can imagine’: Illumina and Grail CEOs defend their deal to investors
Shares of Illumina, the leader in DNA sequencing, have dropped 13% since news leaked last…
STAT Plus: Pharmalittle: In political ploy, Trump promises drug coupons to seniors; N.Y. plans its own Covid-19 vaccine reviews
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Medical AI systems are disproportionately built with data from just three states, new research finds
Late last year, Stanford University researcher Amit Kaushal and a collaborator noticed something striking while…
STAT Plus: Not by the numbers: Former Aceto controller is charged with insider trading
File this under ‘What was he thinking?’ After spending nearly 17 years as controller at…
STAT Plus: A sadly familiar disappointment in Alzheimer’s research
After years of failed attempts to treat Alzheimer’s disease by targeting a toxic brain plaque…
.jpg)
STAT Plus: Pharmalittle: Trump may not approve FDA emergency use guidelines; U.K. starts world’s first Covid-19 challenge trial
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: Gilead to pay $97 million for allegedly using a charity to pay kickbacks to Medicare patients
Gilead Sciences (GILD) agreed to pay nearly $97 million to resolve allegations that donations it…
STAT Plus: HHS criticizes Lilly for seeking to curtail discounts for safety-net hospitals
In a stern rebuke, the Department of Health and Human Services has taken Eli Lilly…
STAT Plus: Public funding underwrote much of the development of J&J’s drug for TB, analysis finds
Amid ongoing debate over taxpayer dollars used to generate medicines, a new analysis contends that…
STAT Plus: Teladoc’s tussle with Amwell raises questions about defining property rights in digital health
The field of health tech is facing a big question: Can it establish strong patent…
STAT Plus: Pharmalittle: FDA to set new standard for Covid-19 vaccine; J&J starts a one-shot vaccine trial
Hello, everyone, and welcome to the middle of the week. Already, you say? Well, the…
STAT Plus: Q&A: Vivek Murthy, a top Biden adviser, on Covid-19 vaccines, the drug industry, and the future of public health
WASHINGTON — After a years-long hiatus, Vivek Murthy is back in the political spotlight. As…
STAT Plus: FDA proposes a ‘modest’ change to a rule for policing off-label marketing
After years of controversy, the Food and Drug Administration has issued a proposed rule to…
STAT Plus: Novartis sells bonds tied to expanding access to medicines in poor countries
In a first-of-its-kind move by a large drug maker, Novartis (NVS) raised approximately $2.1 billion…
STAT Plus: In another health bet, Amazon expands virtual care program for employees
Amazon is expanding a virtual health care initiative for employees called Amazon Care on Tuesday…
STAT Plus: Pharmalittle: Medicare wouldn’t cover emergency-use Covid-19 vaccines; 156 countries join WHO vaccine effort
Top of the morning to you, and a fine one it is. Baby blue skies…
STAT Plus: Coming for the king: Keytruda dominates the immunotherapy market, but challengers are lining up
Keytruda is the immunotherapy king. In the U.S., the Merck anti-PD1 checkpoint inhibitor is approved…
STAT Plus: The world is racing toward Covid-19 drugs. In normal times, it takes years to get new antivirals out the door
Researchers may be racing to develop new Covid-19 treatments, but normally it has taken slightly…
STAT Plus: Legend Biotech CEO detained in China as part of investigation
Legend Biotech’s man in charge will be working from home for the time being. The…
STAT Plus: Senators urge bankruptcy judge to prevent Purdue from paying its CEO a $3.5 million bonus
A group of U.S. senators is urging a bankruptcy judge to prevent Purdue Pharma from…
STAT Plus: Pharmalittle: Azar bars FDA from signing new rules; AstraZeneca reveals Covid-19 vaccine trial protocol
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Teladoc accuses Amwell of infringing on its telehealth patents
Telehealth provider Teladoc last week accused Amwell of infringing on its patents and demanded that…
How Pinterest beat back vaccine misinformation — and what Facebook could learn from its approach
The battle over misinformation amid the Covid-19 pandemic has pitted health experts, parts of the…
STAT Plus: Amgen’s KRAS-blocking cancer drug shows durable responses, with tempered expectations
Amgen said Sunday that patients with advanced lung cancer who were given its drug to…
STAT Plus: New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market
Patients with advanced kidney cancer live longer when treated with a combination of drugs from…
STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition
When Gilead Sciences announced its $21 billion acquisition of Immunomedics one week ago, Gilead executives…
STAT Plus: Pharmalittle: Roche says its drug helped Covid-19 patients; Trump expected to finalize drug importation plan
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: 5 takeaways from venture capital’s growing focus on mental health
Research suggests that only half of the tens of millions of people in the U.S….
State treasurers urge Gilead to lower the price of remdesivir and not pursue “unreasonable profits”
Nearly a dozen state treasurers are asking Gilead Sciences (GILD) to lower the price of…
STAT Plus: Amwell rides IPO wave with expanded stock sale
Taking advantage of a pickup in demand for new stocks, American Well Corp. expanded its…
STAT Plus: Pharmalittle: Biden-aligned group releases drug-pricing plan; U.S. to ship Covid-19 vaccines lickety-split
Rise and shine, everyone, another busy day is on the way. Most days are quite…
STAT Plus: Biden-aligned group outlines potential Day 1 drug pricing actions
WASHINGTON — A leading think tank aligned with the Democratic Party is laying the groundwork…
STAT Plus: The cost of Gilead’s HIV prevention pill thwarted widespread use, study finds
The escalating cost of the only HIV prevention pill may have been a key factor…
STAT Plus: In research on pigs, scientists test a new way to boost recovery after a heart attack
Scientists have developed a new strategy that uses exosomes — tiny, RNA-loaded packets that cells…
STAT Plus: With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses
Illumina, the dominant maker of machines to sequence DNA, is in talks to purchase Grail,…
STAT Plus: Pharmalittle: Lilly drug helped Covid-19 patients; FDA confirms AstraZeneca vaccine trial is on hold
Top of the morning to you, and a fine one it is. Once again, a…